SCHEMBL796113

SCHEMBL796113

CC(=O)Cl.Cc1ccc(S(=O)(=O)NC(CCCCN)C(=O)O)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 10/20 0.70
MMP2 P08253 9/20 0.70
ITGB3 P05106 1/20 0.53
ITGA2B P08514 1/20 0.53
TDP1 Q9NUW8 1/20 0.52
MMP13 P45452 3/20 0.51
MMP3 P08254 2/20 0.51
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
MMP8 P22894 1/20 0.47
ADAMTS4 O75173 1/20 0.47
PLAU P00749 1/20 0.47
HPN P05981 1/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
MMP1 P03956 1/20 0.45
MMP7 P09237 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL232590 1.00 MMP9 (0.70) MMP9MMP2ITGB3ITGA2BTDP1
Hydrochloric Acid SCHEMBL14059216 0.99 MMP9 (0.68) MMP9MMP2ITGB3ITGA2BTDP1
Hydrochloric Acid SCHEMBL28895937 0.99 MMP9 (0.68) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL8322406 0.96 MMP9 (0.71) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL10585071 0.95 MMP9 (0.76) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL457772 0.95 MMP9 (0.76) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL8001084 0.95 MMP9 (0.76) MMP9MMP2ITGB3ITGA2BTDP1
Hydrochloric Acid SCHEMBL9087107 0.94 MMP9 (0.74) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL158952 0.91 MMP9 (0.70) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL158951 0.91 MMP9 (0.70) MMP9MMP2ITGB3ITGA2BTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10307505-B2 Wound dressings for the controlled release of therapeutic agents KCI USA, INC. (US) 2019-06-04 US claimed
US-20170333592-A1 Wound Dressings For The Controlled Release Of Therapeutic Agents SYSTAGENIX WOUND MANAGEMENT, LIMITED (GB) 2017-11-23 US claimed
US-9687581-B2 Wound dressings for the controlled release of therapeutic agents KCI USA, INC. (US) 2017-06-27 US claimed
CN-105044335-B Immunochromatographic test strip for rapid detection of ancylostomiasis infection and preparation method thereof 中国疾病预防控制中心寄生虫病预防控制所 2017-01-25 CN claimed
CN-105044335-A Immunochromatographic test strip for rapid detection of ancylostomiasis infection and preparation method thereof NAT INST OF PARASITIC DISEASES CHINESE CT FOR DISEASE CONTROL AND PREVENTION 2015-11-11 CN claimed
US-20150098985-A1 WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC KCI USA, INC. 2015-04-09 US claimed
EP-1687039-B1 WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS ETHICON INC (US) 2009-01-28 EP claimed
EP-0720657-B1 BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY 3M INNOVATIVE PROPERTIES CO (US) 2007-08-15 EP claimed
US-20070148214-A1 Wound dressing for the controlled release of therapeutic agents KCI USA, INC. 2007-06-28 US claimed
EP-1687039-A1 WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS ETHICON, INC. (US) 2006-08-09 EP claimed
WO-2005051441-A1 WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS ETHICON, INC. (US) 2005-06-09 WO claimed
CN-117858728-A Chelating compounds for the treatment of substance use disorders and uses thereof 可利尔科学公司 2024-04-09 CN disclosed
EP-4135660-A1 COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS Atossa Therapeutics, Inc. (US) 2023-02-22 EP disclosed
WO-2021211808-A1 COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS ATOSSA THERAPEUTICS, INC. (US) 2021-10-21 WO disclosed
US-20200221753-A1 TEXTURED INGESTIBLE PRODUCTS EETBE INC (US) 2020-07-16 US disclosed
CN-1352682-A Cysteine protease and inhibitors for the prevention and treatment of neurocysticercosis UNIV GEORGIA RESAERCH FOUNDATI (US) 2002-06-05 CN disclosed
US-20020058288-A1 Compound for use in the detection and prevention of parasitic infection of humans AKZO NOBEL N.V. (NL) 2002-05-16 US disclosed
EP-0720657-A1 BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY NORTH AMERICAN SCIENCE ASSOCIATES INCORPORATED (US) 1996-07-10 EP disclosed
US-5486459-A Biologically relevant methods for the rapid determination of sterility MEDICAL COLLEGE OF OHIO (US) 1996-01-23 US disclosed
WO-1995008639-A1 BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY NORTH AMERICAN SCIENCE ASSOCIATES, INC. (US) 1995-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058288-A1 Compound for use in the detection and prevention of parasitic infection of humans CD4, OGA, GPI MMP9 3744/4885MMP2 1576/4885ITGB3 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.